How to Select Patients for iTBS in Schizophrenia Negative Symptoms
How should clinicians identify which patients with schizophrenia match the population studied for experimental iTBS targeting predominant negative symptoms?
Clinicians considering neuromodulation for schizophrenia need to know whether a patient resembles the highly selected population studied here. This guide applies to adults with longstanding negative symptoms in whom a clinician is considering experimental left DLPFC iTBS rather than routine evidence-based treatment.
-
Confirm schizophrenia diagnosis and chronic negative symptom predominance
Include only patients who meet ICD-10 clinical criteria for schizophrenia. In this study, eligible patients had predominant negative symptoms for at least 2 years, so the workflow applies to persistent rather than recent or fluctuating symptom presentations.
-
Check core eligibility thresholds
Match the study population by confirming age 18 to 60 years and right-handedness. Require a SANS score of 60 or higher and a SAPS score of 50 or lower, indicating substantial negative symptoms without marked positive symptom burden.
-
Verify medication stability before treatment
Only proceed if the patient is clinically stable on unchanged antipsychotic treatment for at least 4 weeks before enrollment. In the study, patients continued prescribed antipsychotics during the intervention, so this protocol was tested as an adjunct rather than a replacement strategy.
-
Screen for exclusionary psychiatric comorbidity
Exclude patients with comorbid depressive disorder, bipolar affective disorder, or substance abuse or dependence within the past year other than nicotine and caffeine. The study assessed these exclusions with the MINI to reduce confounding from secondary causes of negative symptoms.
-
Review protocol-limiting and safety exclusions
Exclude patients with Axis II personality disorders that would interfere with protocol adherence, standard TMS contraindications, or known or suspected pregnancy. These exclusions defined the safety and feasibility boundaries of the study population.
-
Set expectations before offering experimental treatment
Explain that in this trial, active left DLPFC iTBS did not outperform sham on negative symptoms at posttreatment or through 6 months, even though both groups improved over time. If a patient fits this chronic, clinically stable profile, do not frame this specific protocol as having proven efficacy for negative symptoms.
Clinical Considerations
- These selection criteria reflect a narrow research population and do not establish who will benefit from iTBS in general clinical practice.
- The study could not fully separate primary from secondary negative symptoms, so symptom overlap may still affect applicability even after screening.
- Patients were required to be right-handed and 18 to 60 years old, which limits generalizability outside those groups.
- The trial enrolled clinically stable patients on unchanged antipsychotics, so the findings may not apply to acutely unstable patients or those undergoing medication changes.
Bottom Line
Use this study only to identify a highly selected, clinically stable schizophrenia population with longstanding predominant negative symptoms, not to justify expecting this iTBS protocol to work better than sham.
